Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
Commentary

The new GFR equations: How will eliminating the race coefficient affect Black patients?

Paul Merchant, MD, Crystal Gadegbeku, MD, FAHA, FACP, FASN, Ali Mehdi, MD, Med, FACP, FASN, George Thomas, MD, FACP, Georges Nakhoul, MD, MEd and Jonathan Taliercio, DO, FASN
Cleveland Clinic Journal of Medicine November 2023, 90 (11) 685-691; DOI: https://doi.org/10.3949/ccjm.90a.22061
Paul Merchant
Department of Kidney Medicine, Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Find this author on Cleveland Clinic
Crystal Gadegbeku
Department Chair, Department of Kidney Medicine Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Find this author on Cleveland Clinic
Ali Mehdi
Department of Kidney Medicine, Cleveland Clinic, Cleveland, OH; Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Find this author on Cleveland Clinic
George Thomas
Director, Center for Blood Pressure Disorders, Department of Kidney Medicine, Cleveland Clinic, Cleveland, OH; Associate Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Find this author on Cleveland Clinic
Georges Nakhoul
Director, Center for Chronic Kidney Disease, Department of Kidney Medicine, Cleveland Clinic, Cleveland, OH; Associate Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Find this author on Cleveland Clinic
Jonathan Taliercio
Program Director, Nephrology and Hypertension Fellowship, Department of Kidney Medicine, Cleveland Clinic, Cleveland, OH; Associate Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Find this author on Cleveland Clinic
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    Nonlinear relationship of serum creatinine to the glomerular filtration rate.

Tables

  • Figures
    • View popup
    TABLE 1

    Non-GFR determinants of creatinine and cystatin C

    Increase serum creatinine concentration
    Muscle mass
    Protein intake
    Rhabdomyolysis
    Increase serum cystatin C
    Male
    Older age
    Obesity
    Smoking
    Hyperthyroidism (hypothyroidism decreases it)
    Glucocorticoid therapy
    Inflammatory markers (C-reactive protein)
    Malignancy
    Consider ordering serum cystatin C GFR
    In patients at the extremes of muscle mass or cachexia
    When the serum creatinine concentration is elevated without urinary or radiologic evidence of kidney damage
    When a more precise GFR measurement will change treatment decisions
    • GFR = glomerular filtration rate

    • View popup
    TABLE 2

    Potential patient impacts of the 2021 CKD-EPI equations

    Positive impacts
    Earlier nephrology referral for Black patients
    Earlier recognition and treatment of chronic kidney disease in Black patients
    Earlier referral for transplant evaluation
    Increased patient trust in the healthcare system
    Negative impacts
    Exclusion of medications restricted by GFR cutoff (eg, metformin, sodium-glucose cotransporter 2 inhibitors, and some chemotherapy agents)
    Dose reductions of critical medications (eg, antibiotics, antivirals, and some chemotherapy)
    Exclusion from clinical trials or organ donation based on chronic kidney disease, chronic kidney disease stage, or GFR cutoff
    Substandard imaging due to avoidance or reduction of contrast use
    Increased medical insurance, life insurance costs
    Increased patient anxiety from the diagnosis
    Neutral or unclear impacts
    Reclassification of chronic kidney disease stage
    Changes in estimates of prevalence of chronic kidney disease
    • CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration study; GFR = glomerular filtration rate

PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 90 (11)
Cleveland Clinic Journal of Medicine
Vol. 90, Issue 11
1 Nov 2023
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The new GFR equations: How will eliminating the race coefficient affect Black patients?
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The new GFR equations: How will eliminating the race coefficient affect Black patients?
Paul Merchant, Crystal Gadegbeku, Ali Mehdi, George Thomas, Georges Nakhoul, Jonathan Taliercio
Cleveland Clinic Journal of Medicine Nov 2023, 90 (11) 685-691; DOI: 10.3949/ccjm.90a.22061

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The new GFR equations: How will eliminating the race coefficient affect Black patients?
Paul Merchant, Crystal Gadegbeku, Ali Mehdi, George Thomas, Georges Nakhoul, Jonathan Taliercio
Cleveland Clinic Journal of Medicine Nov 2023, 90 (11) 685-691; DOI: 10.3949/ccjm.90a.22061
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • HEALTH DISPARITIES IN BLACK AMERICANS
    • DIRECTLY MEASURING THE GFR: THE GOLD STANDARD, BUT CUMBERSOME
    • CREATININE AND CYSTATIN C ARE ENDOGENOUS MARKERS
    • SERUM CREATININE-BASED AND CYSTATIN C-BASED EQUATIONS
    • CLINICAL CONSEQUENCES
    • TAKE-HOME POINTS
    • DISCLOSURES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Commentary

  • Respiratory virus season: Strategies for successful navigation
  • Matter of the heart: Prioritizing harm reduction in managing infective endocarditis associated with injection drug use
  • Effective but inaccessible antiobesity medications: A call for sharing responsibility for improving access to evidence-based care
Show more Commentary

Nephrology

  • What is the role for terlipressin in hepatorenal syndrome?
  • Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?
Show more Nephrology

Similar Articles

Subjects

  • Nephrology

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire